Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL-Reference-Cited by-同舟云学术

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL

Published:2015-10-29 Issue:18 Volume:126 Page:2110-2117
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Guièze Romain¹²,Robbe Pauline³,Clifford Ruth³,de Guibert Sophie⁴,Pereira Bruno⁵,Timbs Adele³,Dilhuydy Marie-Sarah⁶,Cabes Maite³,Ysebaert Loïc⁷,Burns Adam³,Nguyen-Khac Florence⁸,Davi Frédéric⁸,Véronèse Lauren⁹¹⁰,Combes Patricia⁹¹⁰,Le Garff-Tavernier Magali⁸,Leblond Véronique¹¹,Merle-Béral Hélène⁸,Alsolami Reem³,Hamblin Angela³,Mason Joanne³,Pettitt Andrew¹²,Hillmen Peter¹³,Taylor Jenny¹⁴,Knight Samantha J. L.¹⁴,Tournilhac Olivier¹²,Schuh Anna³

Affiliation:

1. Service d’Hématologie Clinique Adulte et de Thérapie Cellulaire, Centre Hospitalier Universitaire (CHU) de Clermont-Ferrand, Clermont-Ferrand, France;

2. Equipe d'accueil (EA) 7283-Cancer Resistance Exploring and Targeting (CREAT), Centre d'Investigation Clinique (CIC) 501, Université d’Auvergne, Clermont-Ferrand, France;

3. Oxford Molecular Diagnostics Centre, University of Oxford, Oxford, United Kingdom;

4. Service d’Hématologie Clinique, CHU de Rennes, Rennes, France;

5. Departement de Biostatistiques, CHU de Clermont-Ferrand, Clermont-Ferrand, France;

6. Service d'Hématologie Clinique et Thérapie Cellulaire, CHU de Bordeaux, Bordeaux, France;

7. Service d’Hématologie, CHU de Toulouse, Toulouse, France;

8. Service d'Hématologie Biologique, Assistance Publique des Hôpitaux de Paris (APHP) La Pitié-Salpétrière, Paris, France;

9. Laboratoire de Cytogénétique, CHU de Clermont-Ferrand, Clermont-Ferrand, France;

10. EA4677-Equipe de Recherche sur les Traitements Individualisés des Cancers en Auvergne (ERTICA), Université d’Auvergne, Clermont-Ferrand, France;

11. Service d'Hématologie Clinique, APHP La Pitié-Salpétrière, Paris, France;

12. Royal Liverpool and Broadgreen University Hospitals National Health Service Trust, Liverpool, United Kingdom;

13. Department of Hematology/Oncology, St-James University Hospital, Leeds, United Kingdom; and

14. Oxford National Institute for Health Research (NIHR) Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom

Abstract

Key Points Targeted NGS of relapsed/refractory CLL reveals a high incidence of concurrent mutations that mostly affect the TP53, ATM, and SF3B1 genes. Concurrent mutations of the TP53, ATM, and/or SF3B1 genes confer short survival in patients with relapsed/refractory CLL.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/18/2110/1389519/2110.pdf

Reference43 articles.

1. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.;Furman;N Engl J Med,2014

2. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.;Byrd;N Engl J Med,2013

3. Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia.;Guièze;Blood,2015

4. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.;Wang;N Engl J Med,2011

5. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.;Puente;Nature,2011

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytogenetics in the management of chronic lymphocytic leukemia: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH);Current Research in Translational Medicine;2023-10

2. Prognostic Markers in the Era of Targeted Therapies;Acta Haematologica;2023-09-13

3. Genomic Stratification of Hematological Malignancies;HemaSphere;2023-05-25

4. Diagnosis and Treatment of Chronic Lymphocytic Leukemia;JAMA;2023-03-21

5. Precision diagnostics in chronic lymphocytic leukemia: Past, present and future;Frontiers in Oncology;2023-03-21